

CITATION REPORT

List of articles citing

Tadalafil in primary pulmonary arterial hypertension

DOI: 10.7326/0003-4819-141-9-200411020-00033
Annals of Internal Medicine, 2004, 141, 743-4.

Source: <https://exaly.com/paper-pdf/36360871/citation-report.pdf>

Version: 2024-04-23

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
41	Tadalafil: Pulmonary Hypertension (Adults). <i>Hospital Pharmacy</i> , 2005 , 40, 225-232	1.1	
40	Drug treatment of pulmonary arterial hypertension: current and future agents. <i>Drugs</i> , 2005 , 65, 1337-54	12.1	40
39	Tadalafil improves quality of life and exercise tolerance in idiopathic pulmonary arterial hypertension. <i>International Journal of Cardiology</i> , 2006 , 108, 429-31	3.2	38
38	Pharmacologic treatment for pulmonary arterial hypertension. <i>Current Opinion in Cardiology</i> , 2006 , 21, 561-8	2.1	9
37	Experimental therapies for hypoxia-induced pulmonary hypertension during acute lung injury. <i>Shock</i> , 2006 , 25, 214-26	3.4	19
36	[Beneficial effect of sildenafil following surgery for mitral stenosis complicated by pre-capillary pulmonary hypertension: report of two cases]. <i>Annales De Cardiologie Et D'Angiologie</i> , 2006 , 55, 286-90	0.5	1
35	Efficacy of oral tadalafil, a new long-acting phosphodiesterase-5 inhibitor, for the short-term treatment of pulmonary arterial hypertension in a dog. <i>Transboundary and Emerging Diseases</i> , 2006 , 53, 129-33		15
34	The effects of chronic phosphodiesterase-5 inhibitor use on different organ systems. <i>International Journal of Impotence Research</i> , 2007 , 19, 139-48	2.3	45
33	Current therapies for pulmonary arterial hypertension. <i>Seminars in Cardiothoracic and Vascular Anesthesia</i> , 2007 , 11, 137-48	1.4	3
32	Goal-oriented treatment and combination therapy for pulmonary arterial hypertension. <i>Yearbook of Pulmonary Disease</i> , 2007 , 2007, 194-196		
31	The nitric oxide/cGMP signaling pathway in pulmonary hypertension. <i>Clinics in Chest Medicine</i> , 2007 , 28, 143-67, ix	5.3	66
30	Combination therapy with prostacyclin and tadalafil for severe pulmonary arterial hypertension: a pilot study. <i>Respirology</i> , 2008 , 13, 916-8	3.6	29
29	Pharmacokinetic interaction between tadalafil and bosentan in healthy male subjects. <i>Journal of Clinical Pharmacology</i> , 2008 , 48, 610-8	2.9	85
28	Medical therapy for pulmonary arterial hypertension. <i>Expert Opinion on Pharmacotherapy</i> , 2008 , 9, 65-8	14	7
27	Sustained benefit of tadalafil in patients with pulmonary arterial hypertension with prior response to sildenafil: a case series of 12 patients. <i>International Journal of Cardiology</i> , 2008 , 125, 416-7	3.2	23
26	Tadalafil improves oxygenation in a model of newborn pulmonary hypertension. <i>Pediatric Critical Care Medicine</i> , 2008 , 9, 330-2	3	20
25	Cyclic GMP signaling in cardiovascular pathophysiology and therapeutics. <i>Pharmacology & Therapeutics</i> , 2009 , 122, 216-38	13.9	273

24	Non-congenital heart disease associated pediatric pulmonary arterial hypertension. <i>Progress in Pediatric Cardiology</i> , 2009 , 27, 13-23	0.4	18
23	Tadalafil therapy for pulmonary arterial hypertension. <i>Circulation</i> , 2009 , 119, 2894-903	16.7	769
22	High altitude, a natural research laboratory for the study of cardiovascular physiology and pathophysiology. <i>Progress in Cardiovascular Diseases</i> , 2010 , 52, 451-5	8.5	25
21	The emergence of oral tadalafil as a once-daily treatment for pulmonary arterial hypertension. <i>Vascular Health and Risk Management</i> , 2010 , 6, 273-80	4.4	21
20	Tadalafil for the treatment of pulmonary arterial hypertension. <i>Expert Opinion on Pharmacotherapy</i> , 2010 , 11, 127-32	4	27
19	Tadalafil for the treatment of pulmonary arterial hypertension. <i>Expert Review of Respiratory Medicine</i> , 2011 , 5, 315-28	3.8	7
18	Clinical efficacy of phosphodiesterase-5 inhibitor tadalafil in Eisenmenger syndrome--a randomized, placebo-controlled, double-blind crossover study. <i>Congenital Heart Disease</i> , 2011 , 6, 424-31	3.1	64
17	Tadalafil: a long-acting phosphodiesterase-5 inhibitor for the treatment of pulmonary arterial hypertension. <i>Clinical Therapeutics</i> , 2011 , 33, 993-1004	3.5	27
16	Long-acting phosphodiesterase 5 inhibitor, tadalafil, and superoxide dismutase mimetic, tempol, protect against acute hypoxia-induced pulmonary hypertension in rats. <i>Human and Experimental Toxicology</i> , 2012 , 31, 626-36	3.4	16
15	Pulmonary hypertension-"state of the art" management in 2012. <i>Indian Heart Journal</i> , 2012 , 64, 60-73	1.6	2
14	Tadalafil for the treatment of pulmonary arterial hypertension. <i>Expert Opinion on Pharmacotherapy</i> , 2012 , 13, 747-55	4	13
13	Portopulmonary hypertension: an update. <i>Liver Transplantation</i> , 2012 , 18, 881-91	4.5	73
12	Reactive oxygen and nitrogen species in pulmonary hypertension. <i>Free Radical Biology and Medicine</i> , 2012 , 52, 1970-86	7.8	138
11	Oral therapies for pulmonary arterial hypertension: endothelin receptor antagonists and phosphodiesterase-5 inhibitors. <i>Clinics in Chest Medicine</i> , 2013 , 34, 811-24	5.3	4
10	Tadalafil as monotherapy and in combination regimens for the treatment of pulmonary arterial hypertension. <i>Therapeutic Advances in Respiratory Disease</i> , 2013 , 7, 39-49	4.9	13
9	Efficacy of sildenafil in HIV-related pulmonary arterial hypertension. <i>Journal of Cardiovascular Medicine</i> , 2015 , 16 Suppl 2, S136-7	1.9	4
8	The limits of oral therapy in pulmonary arterial hypertension management. <i>Therapeutics and Clinical Risk Management</i> , 2015 , 11, 1731-41	2.9	7
7	Clinical utility of tadalafil in the treatment of pulmonary arterial hypertension: an evidence-based review. <i>Core Evidence</i> , 2015 , 10, 99-109	4.9	19

6	Safety and effectiveness of tadalafil in patients with pulmonary arterial hypertension: Japanese post-marketing surveillance data. <i>Current Medical Research and Opinion</i> , 2017 , 33, 963-971	2.5	2
5	The Noncanonical Pathway for In Vivo Nitric Oxide Generation: The Nitrate-Nitrite-Nitric Oxide Pathway. <i>Pharmacological Reviews</i> , 2020 , 72, 692-766	22.5	53
4	Pharmacokinetic and Bioequivalence Evaluation of 2 Tadalafil Tablets in Healthy Male Chinese Subjects Under Fasting and Fed Conditions. <i>Clinical Pharmacology in Drug Development</i> , 2021 ,	2.3	1
3	Use of tadalafil for treating pulmonary arterial hypertension secondary to chronic obstructive pulmonary disease. <i>Korean Journal of Internal Medicine</i> , 2007 , 22, 37-9	2.5	4
2	PDE5 Inhibitors and the cGMP Pathway in Pulmonary Arterial Hypertension. 2008 , 305-319		
1	Tadalafil: the evidence for its clinical potential in the treatment of pulmonary arterial hypertension. <i>Core Evidence</i> , 2008 , 2, 225-31	4.9	2